The disruption of a single type of cell has been identified as a significant factor in the emergence of autism by a team led by UC San Francisco scientists.
The finding, reported in the November 21, 2013 issue of Cell, was made with techniques developed only within the last few years, and marks a turning point in autism spectrum disorders (ASDs) research.
Large-scale gene sequencing projects are revealing hundreds of autism-associated genes, and scientists have begun to leverage new methods to decipher how mutations in these disparate genes might converge to exert their effects in the developing brain.
Led by Jeremy Willsey, a graduate student in the laboratory of senior author Matthew W. State, MD, PhD, of UC San Francisco (UCSF), the group showed that this set of genes contributes to abnormalities in brain cells known as cortical projection neurons in the deepest layers of the developing prefrontal cortex during the middle period of fetal development.
Though a range of developmental scenarios in multiple brain regions are surely at work in ASDs, the ability to place these specific genetic mutations in one specific set of cells -- among hundreds of cell types in the brain, and at a specific time point in human development -- is a critical step in beginning to understand how autism comes about.
"Given the small subset of autism genes we studied, I had no expectation that we would see the degree of spatiotemporal convergence that we saw," said State, chair of the Department of Psychiatry at UCSF and an international authority on the genetics of neurodevelopmental disorders.
"This strongly suggests that though there are hundreds of autism risk genes, the number of underlying biological mechanisms will be far fewer. This is a very important clue to advance precision medicine for autism toward the development of personalized and targeted therapies."
ASDs, marked by deficits in social interaction and language development, as well as by repetitive behaviors and/or restricted interests, are known to have a strong genetic component.
But these disorders are exceedingly complex, with considerable variation in symptoms and severity, and there does not appear to be a small collection of mutations widely shared among all affected individuals that always lead to ASDs.
Instead, with the rise of new sequencing methods over the past several years, researchers have identified many rare, non-inherited, spontaneous mutations that appear to act in combination with other genetic and non-genetic factors to cause ASDs. According to some estimates, mutations in as many as than 1,000 genes could play a role in the development of these disorders.
While researchers have been heartened that specific genes are now rapidly being tied to ASDs, State said the complex genetic architecture of ASDs is also proving to be challenging. "If there are a thousand genes in the population that can contribute to risk in varying degrees and each has multiple developmental functions, it is not immediately obvious how to move forward to determine what is specifically related to autism. And without this, it is very difficult to think about how to develop new and better medications."
To begin to grapple with those questions, the researchers involved in the new study first selected as "seeds" the nine genes that have been most strongly tied to ASDs in recent sequencing research from their labs and others. Importantly, these nine genes were chosen solely because of the statistical evidence for a relationship to ASDs, not because their function was known to fit a theory of the cause of ASDs. "We asked where the leads take us, without any preconceived idea about where they should take us," said State.
The team then took advantage of BrainSpan, a digital atlas assembled by a large research consortium, including co-author Nenad Šestan, MD, PhD, and colleagues at Yale School of Medicine. Based on donated brain specimens, BrainSpan documents how and where genes are expressed in the human brain over the lifespan. The scientists, who also included Bernie Devlin, PhD, of The University of Pittsburgh School of Medicine, Kathryn Roeder, PhD, of Carnegie-Mellon University, and James Noonan, PhD, of Yale School of Medicine, used this tool to investigate when and where the nine seed genes join up with other genes in "co-expression networks" to wire up the brain or maintain its function.
The resulting co-expression networks were then tested using a variety of pre-determined criteria to see if they showed additional evidence of being related to ASDs. Once this link was established, the authors were then able to home in on where in the brain and when in development these networks were localizing, which proved to be in cortical projection neurons found in layers 5 and 6 of the prefrontal cortex, and during a time period spanning 10 to 24 weeks after conception. Notably, a study using different methods and published in the same issue of Cell also implicates cortical projection neurons in ASDs.
"To see these gene networks as highly connected as they are, as convergent as they are, is quite amazing," said Willsey "An important outcome of this study is that for the first time it gives us the ability to design targeted experiments based on a strong idea about when and where in the brain we should be looking at specific genes with specific mutations."
In addition to its importance in ASD research, State sees the new work as a reflection of the tremendous value of "big science" efforts, such as large-scale collaborative genomic studies and the creation of foundational resources such as the BrainSpan atlas.
"We couldn't have done this even two years ago," State said, "because we didn't have the key ingredients: a set of unbiased autism genes that we have confidence in, and a map of the landscape of the developing human brain. This work combines large-scale '-omics' data sets to pivot into a deeper understanding of the relationship between complex genetics and biology."